ClinicalTrials.gg
Active, not recruitingNCT05067621Updated Apr 15, 2026

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

A Phase 2 interventional study of Semaglutide Pen Injector and Placebo in Type 2 Diabetes Mellitus, Impaired Glucose Tolerance and Non-Alcoholic Fatty Liver Disease, sponsored by Yale University. Active, not recruiting at 1 site in United States. Open to participants aged 10 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
10 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
114th of 163
60 · median 104
Started
2023
with 19 others
Phase 2
10 of 163
1 open now
Primary completion
2026-12
later than 19 of 44 live
Registered
90th of 163
by date

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 114th largest by enrollment, is one of 20 that started in 2023, is one of 10 in phase 2, reaches primary completion later than 19 of the 44 other live ones, and was the 90th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 10 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.

Read the detailed description

In a recent publication by the TODAY Group Study, it was reported that "diabetes-related complications appear early in youth-onset T2D and accumulate rapidly at a mean age of 26.4 years," and 60.1% of participants developed at least one microvascular complication. The same has been reported in RISE Studies and was suggested that the rapid decline in β-cell function and its insensitivity to two of the most frequently used treatments for T2D in pediatrics is further aggravated by the rising prevalence in NAFLD. These alarming results indicate a pressing need for effective and innovative approaches at preserving β-cell function and reducing hepatic steatosis in obese youth in order to prevent disease progression and associated complications.

This study will provide mechanistic insights in support of a GLP-1 analog, Semaglutide, 2.4 mg weekly, therapy for prediabetes, new onset T2D and NAFLD in youth. The study design is a randomized, double-blind, placebo-controlled, clinical trial (RCT) using Semaglutie (Wegovy up to 2.4mg) for 6 months followed by a wash-out period of 3 months.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Impaired Glucose Tolerance
  • Non-Alcoholic Fatty Liver Disease
  • Obesity, Childhood

Keywords

  • Prediabetes
  • NAFLD
  • Impaired Glucose Tolerance
  • Semaglutide
04

Who can participate

Ages eligible
10 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed with Pre-impaired glucose tolerance (pre-IGT) (2h glucose ≥ 130 mg/dl to ≤ 200 mg/dl post-OGTT) OR impaired glucose tolerance (2h glucose ≥140 to \<200 mg/dl post-OGTT OR ≥5.7% to \<6.5%), OR new-onset T2D (≤24 months duration, 2h glucose >200 and HbA1c >6.5% to10%) treated with stable metformin dose (stable metformin dose is defined as at least 1000 mg daily or the maximum tolerated dose for 12 months or less)
  • PDFF of ≥ 8%
  • Male or female, aged 10 to \<21 years at the day of randomization, in puberty (pubertal stage will be assessed by pediatric Endocrinologists Dr. Samuels and Dr. Hu) (girls and boys: Tanner stage II-IV); girls who begin menstruating must have a negative pregnancy test during the study
  • Weight ≥ 54kg
  • ≥ 85% but ≤ 40 kg/m2
  • Good general health (normal kidney function, amylase, and lipase levels)
  • from a legally acceptable representative (LAR) and child assent from the subject obtained before any trial-related activities (trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial)
  • Ability and willingness to adhere to the protocol including self-measurement of plasma glucose according to the protocol.

Exclusion criteria

Exclusion Criteria

  • Known or suspected to trial product(s) or related products.
  • Receipt of any medicinal product within 30 days before screening.
  • Prepubertal participants (Tanner stage 1)
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using highly effective methods.
  • Having a diagnosis of:

    • Type 1 diabetes o Maturity onset diabetes of the young (MODY) o History or presence of Pancreatitis (acute or chronic) o Presence of endocrinopathies (e.g., Cushing syndrome) o Cardiac, renal or pulmonary or other chronic illness o Known history of heart disease (including history of arrhythmias or conduction delays on , or new clinically significant arrhythmias or conduction delays on ECG identified at visit 1) o Family or personal history of MEN type 2 or medullary thyroid carcinoma (family is defined as a first-degree relative)o Any other disorder which, in the opinion of the investigator, might jeopardize subject's safety or compliance with the protocol
  • Any laboratory safety parameter at screening outside the below extended laboratory ranges: o Baseline creatinine >1.0mg o Hypertriglyceridemia)(>500 mg/dl)

    • Calcitonin equal or above 50 ng/L at screening o (BMI) ≤ 25.0 at the screening visit o ≥5 times the upper normal limit (UNL) o Creatinine >UNL for age in children unless renal function is proven normal by further assessments at the discretion of the investigator
  • Known hypoglycemic unawareness.
  • Recurrent severe hypoglycemic episodes within the last year as judged by the investigator.
  • Uncontrolled hypertension treated or untreated >99th percentile for age and gender in children and adolescents.
  • Treatment with any medication for the indication of diabetes other than stated in the inclusion criteria in a period of 90 days before screening.
  • Taking medication, based on the investigator's judgement, that may cause significant weight gain or loss (e.g., antipsychotic, , anti-obesity medication).
  • Presence or history of malignant neoplasm within 5 years prior to the day of screening.Basal and squamous cell skin cancer and any carcinoma in-situ is allowed.
  • Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies.

Mental health:

  • History of major depressive disorder within 2 years before screening
  • Diagnosis of other severe psychiatric disorders (e.g., schizophrenia, bipolar disorder)
  • A Patient Health Questionnaire-9 (PHQ-9) score of ≥15 at screening
  • A lifetime history of suicidal attempt
  • Suicidal behavior within 30 days before screening
  • Suicidal ideation corresponding to type 4 or 5 based on the Columbia-Suicide Severity
  • Rating Scale (C-SSRS) within the past 30 days before screening
  • Participants with confirmed diagnosis of bulimia nervosa disorder
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Receive treatment

    Semaglutide (Wegovy) pen is a subcutaneous injection

    Drug: Semaglutide Pen Injector

  • Placebo comparator
    Placebo

    The placebo pen is almost exactly the same as the Wegovy subcutaneous injection except it does not contain the active ingredient, Semaglutide.

    Drug: Placebo

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.

    Also known as: Wegovy

  • DrugPlacebo

    Injection pen contains excipients.

06

What researchers measure

Primary outcomes

  1. Change in Oral Disposition Index (oDI)

    The oDI value is the product of total responsivity index and insulin sensitivity. The change in oDI from baseline to 6M on treatment is calculated as the difference between 6M oDI value and baseline oDI value. The oDI measures the ability of beta-cell to respond to a glucose stimulus.

    Time frame: Baseline and 6 months

  2. Change in Protein Density Fat Fraction (PDFF)

    The change in PDFF from baseline to 6M on treatment is calculated as the difference between 6M PDFF value and Baseline PDFF. It provides an accurate, non-invasive, reproducible, quantitative, and precise estimation of liver fat content. The expected changes in MRI-PDFF from baseline to 6M is ≥ 5.8% reduction compared to the placebo group.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Change in Oral glucose tolerance test (OGTT) derived biomarkers: oDI

    Change in oDI from baseline to 9M after the wash-out period, calculated as the difference between 9M oDI value and baseline oDI value. This is similar to Outcome 1 except measured at 9M.

    Time frame: Baseline and 9 months

  2. Change in OGTT derived biomarkers: fasting insulin

    Change in fasting insulin calculated as 1/Fasting Insulin \[1/IF\] from baseline to 6M.

    Time frame: Baseline and 6 months

  3. Change in OGTT derived biomarkers: fasting insulin

    Change in fasting insulin calculated as 1/Fasting Insulin \[1/IF\] from baseline to 9M.

    Time frame: Baseline and 9 months

  4. Change in OGTT derived biomarkers: c-peptide

    Change in c-peptide from baseline to 6M calculated as \[change in C-peptide from 0-30min\] /\[change in glucose from 0-30 min\]. This computes for early c-peptide response to oral glucose.

    Time frame: Baseline and 6 months

  5. Change in OGTT derived biomarkers: c-peptide

    Change in c-peptide from baseline to 9M calculated as \[change in C-peptide from 0-30min\] /\[change in glucose from 0-30 min\]. This computes for early c-peptide response to oral glucose.

    Time frame: Baseline and 9 months

  6. Change in OGTT derived biomarkers: fasting c-peptide

    Change in fasting c-peptide from baseline to 6M calculated as Fasting C-peptide/Fasting Insulin.

    Time frame: Baseline and 6 months

  7. Change in OGTT derived biomarkers: fasting c-peptide

    Change in fasting c-peptide from baseline to 9M calculated as Fasting C-peptide/Fasting Insulin.

    Time frame: Baseline and 9 months

  8. Time to glucose peak

    Identification of time to glucose peak during OGTT at baseline.

    Time frame: Baseline

  9. Time to glucose peak

    Identification of time to glucose peak during OGTT at 6M.

    Time frame: 6 months

  10. Time to glucose peak

    Identification of time to glucose peak during OGTT at 9M.

    Time frame: 9 months

  11. Glucagon levels

    Identification of glucagon levels during OGTT at baseline.

    Time frame: Baseline

  12. Glucagon levels

    Identification of glucagon levels during OGTT at 6M.

    Time frame: 6 months

  13. Glucagon levels

    Identification of glucagon levels during OGTT at 9M.

    Time frame: 9 months

  14. Incretin effect

    Estimated as the ratio between total insulin responses during OGTT and IVGTT at the end of treatment and expressed as percentage. It is computed by: \[100% × (AUCins OGTT - AUCins IVGTT)/AUCins OGTT\].

    Time frame: 6 months

  15. Incretin effect

    Estimated as the ratio between total insulin responses during OGTT and IVGTT at the end of the wash-out period and expressed as percentage. It is computed by: \[100% × (AUCins OGTT - AUCins IVGTT)/AUCins OGTT\].

    Time frame: 9 months

  16. Change in Protein Density Fat Fraction (PDFF)

    The change in PDFF from baseline to 9M after the wash-out period is calculated as the difference between 9M PDFF value and Baseline PDFF. It provides an accurate, non-invasive, reproducible, quantitative, and precise estimation of liver fat content. The expected changes in MRI-PDFF from baseline to 9M is ≥ 5.8% reduction compared to the placebo group.

    Time frame: Baseline and 9 months

  17. Fractional rates of de Novo Lipogenesis (DNL)

    It is the measure of contribution of hepatic DNL and plasma free fatty acid reesterification to plasma triglyceride secretion at baseline. It is calculated by F = plasma palmitate enrichment/(22 X plasma deuterium enrichment). F is the fraction of palmitate synthesized during the time between the loading dose of the deuterium-labeled water and the collection time.

    Time frame: Baseline

  18. Fractional rates of de Novo Lipogenesis (DNL)

    It is the measure of contribution of hepatic DNL and plasma free fatty acid reesterification to plasma triglyceride secretion at 6M. It is calculated by F = plasma palmitate enrichment/(22 X plasma deuterium enrichment). F is the fraction of palmitate synthesized during the time between the loading dose of the deuterium-labeled water and the collection time.

    Time frame: 6 months

  19. Fractional rates of de Novo Lipogenesis (DNL)

    It is the measure of contribution of hepatic DNL and plasma free fatty acid reesterification to plasma triglyceride secretion at 9M. It is calculated by F = plasma palmitate enrichment/(22 X plasma deuterium enrichment). F is the fraction of palmitate synthesized during the time between the loading dose of the deuterium-labeled water and the collection time.

    Time frame: 9 months

  20. Total cholesterol

    Measure of total cholesterol in plasma taken at 6M.

    Time frame: 6 months

  21. Total cholesterol

    Measure of total cholesterol in plasma taken at 9M.

    Time frame: 9 months

  22. LDL cholesterol

    Measure of LDL cholesterol in plasma taken at 6M.

    Time frame: 6 months

  23. LDL cholesterol

    Measure of LDL cholesterol in plasma taken at 9M.

    Time frame: 9 months

  24. HDL cholesterol

    Measure of HDL cholesterol in plasma taken at 6M.

    Time frame: 6 months

  25. HDL cholesterol

    Measure of LDL cholesterol in plasma taken at 9M.

    Time frame: 9 months

  26. Triglycerides

    Measures of triglycerides in plasma taken at 6M.

    Time frame: 6 months

  27. Triglycerides

    Measures of triglycerides in plasma taken at 9M.

    Time frame: 9 months

Other outcomes

  1. Changes in liver fibrosis

    Changes in fibrosis of the liver as measured by the difference between MRE Stiffness during baseline and 6M.

    Time frame: 6 months

  2. Changes in liver fibrosis

    Changes in fibrosis of the liver as measured by the difference between MRE Stiffness during baseline and 9M.

    Time frame: 9 months

07

Study locations

1 site
  • Pediatric Diabetes Center
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 41 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2021
First posted
Oct 5, 2021
StartActual
Jul 17, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05067621
Lead sponsor
Yale University
Responsible party
Sonia Caprio (Professor, Yale University) — Principal investigator
First posted
Oct 5, 2021
Start date
Jul 17, 2023
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Sonia Caprio, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion